Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100601 | 0.91 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDMEN1 | |
| SCHEMBL21902756 | 0.91 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDMEN1 | |
| SCHEMBL1034120 | 0.90 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL30951580 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL3168608 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL3170774 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL3178525 | 0.85 | HPGD (0.53) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL27808948 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHPGDRXRA | |
| SCHEMBL377079 | 0.82 | MAOB (0.60) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30100607 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHPGDRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1276739-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001081340-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | SMN1; SMN2 1449/4885NPC1 548/4885RAB9A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.